Analysis of 43 patients with newly diagnosed AML (JHU1 cohort; Supplemental Table 1) also revealed that a higher proportion of senescent-like (CD3+CD8+CD57+KLRG1+) T cells in baseline BM samples was associated with significantly worse OS (P = 0.004) after treatment with standard chemotherapy (Figure 2D; optimal cut-point of CD3+CD8+CD57+KLRG1+ T cells = 31.9%). The gene discussed is B3GAT1; the disease is acute myeloid leukemia.